Neuroscientific Biopharmaceuticals Ltd (NSB) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.029x

Based on the latest financial reports, Neuroscientific Biopharmaceuticals Ltd (NSB) has a cash flow conversion efficiency ratio of -0.029x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-480.55K ≈ $-340.02K USD) by net assets (AU$16.81 Million ≈ $11.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NSB equity financing ratio to measure how much of total assets are equity-financed.

Neuroscientific Biopharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Neuroscientific Biopharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Neuroscientific Biopharmaceuticals Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.

Neuroscientific Biopharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Neuroscientific Biopharmaceuticals Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
SHINWON CONSTRUCTION COMPANY Ltd KQ:017000	-0.084x
Glennon Small Companies Ltd AU:GC1	0.011x
Benton Resources Inc V:BEX	-0.034x
NSX Ltd AU:NSX	0.587x
Salona Cotspin Limited NSE:SALONA	0.248x
MSCM Holdings Bhd KLSE:0041	-0.048x
Euromedis Groupe SA PA:ALEMG	0.048x
ESV Inc KQ:223310	-0.381x

Annual Cash Flow Conversion Efficiency for Neuroscientific Biopharmaceuticals Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Neuroscientific Biopharmaceuticals Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Neuroscientific Biopharmaceuticals Ltd worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$16.81 Million ≈ $11.90 Million	AU$-941.33K ≈ $-666.05K	-0.056x	-776.94%
2024-06-30	AU$5.35 Million ≈ $3.79 Million	AU$44.25K ≈ $31.31K	0.008x	+101.68%
2023-06-30	AU$4.69 Million ≈ $3.32 Million	AU$-2.30 Million ≈ $-1.63 Million	-0.491x	+60.97%
2022-06-30	AU$5.52 Million ≈ $3.91 Million	AU$-6.94 Million ≈ $-4.91 Million	-1.258x	-606.05%
2021-06-30	AU$14.60 Million ≈ $10.33 Million	AU$-2.60 Million ≈ $-1.84 Million	-0.178x	+71.50%
2020-06-30	AU$3.65 Million ≈ $2.58 Million	AU$-2.28 Million ≈ $-1.61 Million	-0.625x	-124.79%
2019-06-30	AU$5.06 Million ≈ $3.58 Million	AU$-1.41 Million ≈ $-995.83K	-0.278x	+59.09%
2018-06-30	AU$732.52K ≈ $518.30K	AU$-497.91K ≈ $-352.30K	-0.680x	-95.36%
2017-06-30	AU$535.79K ≈ $379.10K	AU$-186.42K ≈ $-131.90K	-0.348x	+50.65%
2016-06-30	AU$124.47K ≈ $88.07K	AU$-87.76K ≈ $-62.09K	-0.705x	--

About Neuroscientific Biopharmaceuticals Ltd

AU:NSB Australia Biotechnology

Market Cap

$14.12 Million

AU$19.95 Million AUD

Market Cap Rank

#26135 Global

#1174 in Australia

Share Price

AU$0.06

Change (1 day)

+0.00%

52-Week Range

AU$0.06 - AU$0.21

All Time High

AU$0.52